INTRODUCTION

116
Recent improvements in next generation sequencing platforms have paved the way 117 for the highly sensitive detection of ctDNA in plasma specimens. Current strategies 118 for ctDNA analysis may be divided into three categories: 1) patient-specific 119 approaches that utilize personalized assays (1-4); 2) tumor type-specific targeted 120 sequencing that do not require patient-specific optimization (5-7); 3) tumor type-121 independent genome-wide analyses (8) (9) (10) (11) . The first approach is highly sensitive 122 but is technically challenging and expensive. The second approach involves targeted 123 sequencing methods such as CAPP-Seq (5, 6). It is highly sensitive, but is most 124 practical in patients with tumor types that harbor highly recurrent aberrations that 125 can be sequenced with a capture panel of a relatively limited size. DOI: 10.1158 /1078 SNVs, indels and fusion breakpoints. The clinical utility of monitoring ctDNA by 155 CAPP-Seq has been previously demonstrated in patients with lung cancer and 156 diffuse large B cell lymphoma (5, (14) (15) (16) . The second approach, GRP, is based on 157 shallow whole genome sequencing for the assessment of genome-wide copy number 158 alterations and has been shown to detect ctDNA in patients with ovarian carcinoma, 159
Hodgkin lymphoma and follicular lymphoma (9). Successful monitoring of CNAs in 160 plasma has been also described previously in prostate cancer patients (11). In the 161
present study, we demonstrate that the combination of these two techniques 162 enables the reliable monitoring of a wide spectrum of molecular markers in ctDNA 163
and this approach has a significant translational potential in LMS and other cancer 164 types characterized with a comparable genomic complexity. 165 166 167
Research. DOI: 10.1158 /1078 Sequencing data was processed using a custom bioinformatics pipeline and 286 SNV/indel calling was performed as previously described with minor modifications 287 (6). Briefly, sequencing reads were demultiplexed using a 4bp sample index and de-288 duplicated using molecular barcodes. For cfDNA samples, background polishing was 289 performed to reduce stereotypical base substitution errors. SNV/indel calling was 290 performed as previously described (6) with the following modifications. We defined 291 a "blacklist" as the genes in our panel that were found to be recurrently mutated in 292 the plasma sequencing data from 24 healthy controls. Alterations were recurrently 293 observed in four genes in our panel: MLL2, APOBR, PPR21, and DSPP. One or more 294 alterations was observed in each of these genes in >90% of healthy plasma samples 295 and thus these genes were removed from consideration for variant calling in tumor 296 or plasma samples in LMS patients. For tumor genotyping, we applied additional 297 requirements to identify high-confidence somatic variant calls, to account for the 298 possible artifacts in DNA extracted from FFPE tissue (44, 45). We required ≥3 299 supporting duplex reads, a positional depth in tumor and germline ≥ 25% of the 300 selector wide median depth, ≥5% mutant AF in the tumor, ≤1 read in matched 301 germline, and no overlap with the UCSC RepeatMasker track (42, 46). 302
For CAPP-Seq-based ctDNA analysis, cfDNA samples were sequenced to a median 303 de-duplicated depth of 2,031x (Supporting File: Table S4 ) and only somatic 304 mutations that were present in one or more tumor samples were considered. 305 306
Genome representation profiling (GRP) of plasma specimens 307
Sequencing libraries were prepared with the TruSeq Chip preparation kit (Illumina), 308 indexed, and 23 samples were pooled for multiplex sequencing across both lanes of 309
an Illumina HiSeq2500 flow cell. Sequencing was performed in a 1x50bp mode and 310 at least 10 million reads per sample were required from the LMS plasma specimens. 311
Sequencing reads were mapped to the GRCh37/hg19 reference genome using BWA-312 MEM with the default settings (version 0.7.10) (37). The pseudo-autosomal region 313 on chromosome Y was masked in the reference genome. Duplicate reads were 314 removed using SAMtools (version 0.1.18) (38, 47). The sequencing summary 315 statistics are included in Supporting File: Table S5 . Copy number variants in cfDNA 316
were identified using the depth-of-coverage Plasma-Seq algorithm version 0.6 (11), 317 with the following modifications: 1) we used sequencing reads of 50 bp; 2) genome 318 was divided into 100,000, where each window contains the same amount of 319 mappable reads; 3) the average length of the bins was 28 kb; 4) data from 189 320 female and 189 male healthy donors were used as the non-tumor controls. Next we 321 applied Plasma-Seq algorithm with these settings to an independent group of 50 322 healthy donors, to define the genome-wide segmented Z-scores that set the 323 specificity for LMS analysis at 98% (allowing 1/50 healthy donors to carry a CNA in 324
Research. as compared to the other cancer types ( Figure 2C ) (23). As such, we anticipated that 375 the number of SNVs/indels detectable in ctDNA of LMS patients may be 376 substantially lower than it would be for a cancer with higher mutational burden, 377 such as lung cancer, for which a similar approach to selector design and comparable 378 selector size yielded a panel covering an average of 8 mutations per patient (6). 379 380
Performance of CAPP-Seq in LMS patients 381
To assess the performance of our LMS-focused CAPP-Seq approach, we first 382 analyzed 22 DNA samples obtained from spatially and temporally distinct sites of 383 tumors from 7 LMS patients. We identified a median of 1 (range 0 -4) non-384 synonymous SNV/indel in 20/22 tumor specimens ( Figure 2D ). We identified point 385
Research. Figure 2B ), and all mutations identified in these genes were 388 present in each tumor specimen analyzed from each patient ( Figure 2D ), suggesting 389 that these are truncal genetic events, i.e. shared early drivers in the development of 390 LMS. We also found evidence for intra-patient tumor heterogeneity in two patients. 391
In LMS5 and LMS6 we identified mutation in SPEN and PPRC1 that were unique to 392 individual metastatic sites in these patients. Mutations in these genes have been less 393 frequently reported in LMS, and likely represent subclonal events in these patients 394 ( Figure 2D ). 395
We next applied LMS-focused CAPP-Seq to a total of 28 serial plasma samples from 396 the 7 patients, as well as plasma samples from 24 healthy controls to assess 397 specificity of ctDNA detection. Data from cfDNA of healthy donors was used to 398 characterize selector-specific error profiles and perform digital error suppression as 399 described before (6). CAPP-Seq demonstrated a baseline sensitivity of ctDNA 400 detection of 86% (defined as detection of ctDNA at the first blood draw in a patient 401 with known disease, Table 1 , Supplementary Figure S1 ) with a specificity of 98.91% 402 (determined using plasma from the 24 healthy donors) (Supplementary Figure S2) . 403
The overall sensitivity of ctDNA detection across all analyzed samples was 68% Figure S3) . The only 433 consistently truncal CNA, found across all tumors specimens analyzed in patients 434 LMS2, LMS3, LMS4, LMS5 and LMS7, was a 3.5Mb copy number loss on chromosome 435 11q24.3-q25 (Supplementary Figure S3) . This genomic region includes 24 genes 436 (Supplementary Figure S4) , including ADAMTS8 gene (ADAM metallopeptidase with 437 thrombospondin type 1 motif 8, also known as METH2) that has been previously 438 described as a tumor suppressor in multiple types of cancer (25).
439
GRP was performed at a median depth of 0.21x across the whole genome on 27 440 plasma specimens, all of which had been profiled also by CAPP-Seq (Supplementary  441  Table S5 ). We also analyzed GRP data obtained from 378 healthy donors (189 males  442 and 189 females) to calibrate the analysis algorithm, and the data from additional 443 50 healthy donors was used to set the genome-wide z-score cut-off at +/-5.44 that 444 allowed for 98% specificity. Tumor-matched CNAs were detected in plasma 445 specimens of 71% (5/7) of patients, with the overall sensitivity of 44% (12/27) 446 across all samples (Table 1 , Supplementary Figure S1 ). Based on ctDNA 447 quantification by CAPP-Seq, the indicative limit of ctDNA detection by GRP was as 448 low as 0.23% VAF (sample LMS3-C3 Figure 3C and F, Supplementary 463 Figure S1 ). However, in patients LMS1, LMS2, LMS4 and LMS5 we demonstrated 464 that combining CAPP-Seq and GRP might prevent false negative results in ctDNA 465
Research. Figure 3A, B Our results demonstrate the feasibility of a ctDNA-based assessment of treatment 485 response in LMS patients. In two patients, LMS1 and LMS7, the ctDNA signal became 486 undetectable after surgery for a primary extremity tumor and a metastatic liver 487 tumor, respectively ( Figure 3A , F). ctDNA levels in three patients (LMS2, 3 and 4) 488 reflected the initial response to chemo-and radiotherapy ( Figure 3B-D) . In LMS2, 489
monitoring (
we observed a decrease of ctDNA level from 3.66 to 0.27 mutant copies per mL of 490 plasma after the first 110 days of temozolomide treatment. In patient LMS3, ctDNA 491 signal dropped to undetectable levels by CAPP-Seq and GRP after the first two cycles 492 of gemcitabine and docetaxel treatment combined with radiation therapy. In patient 493 LMS4, we showed a gradual decrease of ctDNA levels in the first three plasma 494 samples collected before, during and after completion of aldoxorubicin treatment. 495
All patients analyzed in this study eventually progressed based on imaging studies, 496 which was reflected by the increasing levels of ctDNA in all but one patient ( Figure  497 3). The single patient without evidence of ctDNA during progression (patient LMS7) 498 had metastases in lymph nodes and lung but no metastases in soft tissue. 499
Interestingly, we found a highly significant correlation between presence of ctDNA 500 and the location of metastatic tumors in LMS patients. There was a lower rate of 501 ctDNA-positive plasma samples in patients with metastases located in lymph nodes 502 or lung only, compared to patients with metastatic tumors present also in soft 503 tissues, liver and bone ( Overcoming tumor heterogeneity is a major challenge for the personalized 519 treatment of cancer (26). Cancers are known to vary in their mutational profile at 520 different sites within an individual lesion, as well as across different tumor deposits 521 in metastatic patients (27) (28) (29) . A major advantage of ctDNA compared to tissue 522 biopsies is that ctDNA analysis simultaneously integrates contributions from 523 multiple tumor deposits, enabling a more comprehensive analysis of tumor 524 heterogeneity (15, (30) (31) (32) . Thus, we sought to explore the utility of our approach for 525 the study of tumor heterogeneity in LMS. We profiled multiple tumor specimens per 526 patient (median of 3, range 1 -7) and found evidence for intra-patient heterogeneity 527 of mutations across different lesions in 2/5 of the patients in whom more than 1 528 tumor sample was sequenced ( Figure 2D ). However, these subclonal SNVs were not 529 detected in ctDNA, likely due to the low overall ctDNA levels in these patients. On 530 the other hand, we have observed substantial intra-patient tumor heterogeneity by 531 profiling CNAs (Supplementary Figure S3) . Multiple aberrations were present only 532 in a single sample or in a single region of the same tumor, and some of these 533 subclonal CNAs were detectable in ctDNA. For example, among the 5 plasma 534 specimens from one of these patients (LMS5) we detected a copy number gain of 535 chromosome 1q21.3-q42.12 in the 1st and the 4th plasma samples. We did not 536 detect this aberration in the metastatic tumor removed shortly after the 1st blood 537 sample collection, as we examined only one region of the multifocal abdominal 538 recurrence. But 1/6 subsequent metastatic tumors removed shortly after the 4th 539 blood sample collection harbored the identical chromosomal gain as detected in 540 ctDNA ( Figure 4 ). As has previously been shown for lymphoma and lung cancer (14, 541 15, 23) , the analysis of ctDNA enables detection of subclonal alterations also in LMS. 542 543 544
Research. entities, ctDNA testing needs to be tailored to the genomic profiles of specific types 561 of tumors to achieve clinically relevant sensitivity and specificity. 562 563
Here we present a combinatorial approach to ctDNA monitoring, using LMS as a 564 disease with an intermediate level of both point mutations and copy number 565 aberrations. We describe the application of two previously validated next 566 generation sequencing-based methods for ctDNA detection in a group of seven 567 patients with LMS for whom sequential blood samples were collected. The first 568 method, CAPP-Seq, relies on deep sequencing of a tumor type-specific panel 569 covering the most recurrent SNVs and indels in that disease. CAPP-Seq is an 570 ultrasensitive method for ctDNA detection that is most effective in tumor types with 571 a relatively high rate of recurrent mutations that can be covered by a capture panel 572 of a limited size to ensure cost-effectiveness of deep sequencing, as has been 573 previously demonstrated in lung cancer and lymphoma (5, 14, 15). The second 574 method, GRP, is routinely used for a non-invasive prenatal screening and relies on a 575 low pass whole genome sequencing of cfDNA. GRP has been reported to detect 576 ctDNA in asymptomatic patients with ovarian carcinoma, Hodgkin lymphoma and 577 follicular lymphoma (9). 578 579
In the previous CAPP-Seq studies in lung cancer, a selector designed to detect a 580 median of 8 mutations per tumor yielded a median 6 mutations per tumor when 581 applied to an independent group of patients (6). This number of expected reporters 582 tracked in plasma was high enough to reliably quantify ctDNA with a very high 583 specificity and sensitivity. In the present study, we applied a similar approach to 584
Research. DOI: 10.1158 /1078 design an LMS-specific CAPP-Seq selector based on TCGA data from 77 LMS cases as 585 described previously for lung cancer (5). Our LMS-specific capture panel was 586 expected to detect 3 mutations per LMS tumor. Similar to the lung cancer CAPP-Seq 587 study, we detected a lower than expected number of mutations also in LMS patients 588 (a median of 1 mutation per tumor). The discrepancy between the expected and 589 detected number of SNV/indels in LMS patients is most likely a combination of 1) 590 the selector design being over-fit due to the relatively small number of LMS exomes 591 used to design the panel, 2) the small size of our pilot cohort, 3) the heterogeneity of 592 somatic mutations in this disease, and 4) more stringent analysis criteria applied in 593 CAPP-Seq analysis as opposed to TCGA dataset. Because of the lower than expected 594 number of SNV/indels detected in LMS tumors, we employed a combination 595 approach to simultaneously detect CNAs in tumor and plasma specimens. Separate 596 sequencing of libraries for SNV/indel and CNA analyses may not be practical in the 597 clinical setting. We propose that this strategy could be further improved by 598 developing more robust experimental and bioinformatics methods that would 599 combine targeted detection of SNV/indels with a genome-wide interrogation of copy 600 number changes in a single experiment. 601 602
To obtain the highest level of confidence in the measurement of LMS ctDNA in 603 plasma samples, we required each aberration to be present in patient-matched 604 tumor and plasma specimens, and required each somatic SNV/indel to have duplex 605 support. Our data show that ctDNA could be measured in 86% (6/7) of LMS patients 606 with active disease at >98% specificity, and suggest that the levels of ctDNA 607 correlate with the response to treatment. We demonstrate that the orthogonal 608 analysis of ctDNA using two separate methods increased the number of molecular 609 markers that can be monitored in plasma. By CAPP-Seq, we measured the VAF of 610 each mutation, which can be translated into mutant copies of ctDNA per mL of 611 plasma, an absolute quantification of ctDNA levels. By GRP, it is not possible to 612 perform an absolute measurement of the abundance of ctDNA. Therefore, to 613 represent the GRP data we used the extent of ctDNA with tumor-matched CNAs 614 measured as Mb or the fraction of genome altered by CNAs. While detection of copy 615 number alterations in ctDNA is in principle limited by the mutant allele fraction and 616 the original profile of CNAs in the tumor, GRP provided a good proxy for ctDNA load 617 compared to CAPP-Seq results (Supplementary Figure S5) . We propose that a 618 similar strategy may also prove beneficial in other types of tumors that are 619 characterized by moderate levels of both SNVs/indels and CNAs, such as ovarian, 620 breast or head and neck squamous cell carcinomas (24 DOI: 10.1158 /1078 
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